Previous publications indicated that GLP-1 analogs have significant neuroprotective effects in neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD) and stroke [12, 13]. This evidence concerns the gene GCG and stroke disorder.